Aberdeen Group plc Buys Shares of 693,452 Biohaven Ltd. $BHVN

Aberdeen Group plc bought a new stake in Biohaven Ltd. (NYSE:BHVN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 693,452 shares of the company’s stock, valued at approximately $7,829,000. Aberdeen Group plc owned 0.66% of Biohaven as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BHVN. PNC Financial Services Group Inc. raised its position in Biohaven by 113.7% in the third quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock valued at $36,000 after purchasing an additional 1,268 shares during the period. PFS Partners LLC purchased a new stake in shares of Biohaven in the 3rd quarter valued at $60,000. Elkhorn Partners Limited Partnership raised its holdings in shares of Biohaven by 26.1% in the 2nd quarter. Elkhorn Partners Limited Partnership now owns 5,800 shares of the company’s stock valued at $82,000 after buying an additional 1,200 shares during the period. Focus Partners Wealth purchased a new stake in shares of Biohaven in the 3rd quarter valued at $87,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Biohaven by 198.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,031 shares of the company’s stock valued at $113,000 after buying an additional 5,341 shares during the period. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Morgan Stanley cut their price objective on Biohaven from $26.00 to $21.00 and set an “overweight” rating on the stock in a report on Tuesday, January 6th. Royal Bank Of Canada boosted their price objective on Biohaven from $22.00 to $23.00 and gave the company an “outperform” rating in a report on Tuesday, March 3rd. TD Cowen boosted their price objective on Biohaven from $15.00 to $30.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Leerink Partners reiterated an “outperform” rating and issued a $15.00 price objective on shares of Biohaven in a report on Tuesday, March 3rd. Finally, William Blair reiterated a “market perform” rating on shares of Biohaven in a report on Friday, December 26th. Three research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.64.

Biohaven Trading Up 1.1%

BHVN opened at $9.37 on Thursday. Biohaven Ltd. has a 12 month low of $7.48 and a 12 month high of $24.06. The stock has a market capitalization of $1.41 billion, a price-to-earnings ratio of -1.35 and a beta of 1.34. The company has a debt-to-equity ratio of 4.59, a current ratio of 3.18 and a quick ratio of 3.18. The business has a fifty day moving average price of $10.42 and a 200 day moving average price of $11.69.

Biohaven (NYSE:BHVN) last released its earnings results on Monday, March 2nd. The company reported ($1.21) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.01. Sell-side analysts expect that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.